A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol

What Was Tested

This clinical study looks at hCG (human chorionic gonadotropin).

CG beta is a novel recombinant hCG (rhCG) molecule expressed by a human cell line (PER.C6®) and has a different glycosylation profile compared to urinary hCG or rhCG derived from a Chinese Hamster Ovary (CHO) cell line.

The effect of the unique glycosylation of CG beta and its associated potency implications in women were not known prior to this trial.

Who Took Part

The study group was 620 women.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Neither the women nor the staff measuring them knew who was on hCG (human chorionic gonadotropin), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.

Randomization was stratified by centre and age (30-37 and 38-42 years).

The primary endpoint was the number of good-quality blastocysts (Grade 3 BB or higher).

Triggering with rhCG was performed when 3 follicles were ≥17 mm but no more than 25 follicles ≥12 mm were reached.

What Was Measured

The subject headings attached to it are Anti-Mullerian Hormone, CHO Cells, Chorionic Gonadotropin, Chorionic Gonadotropin, beta Subunit, Human, Cricetinae, Cricetulus and Fertilization in Vitro.

The authors tagged it with the keywords FE 999302, blastocyst quality, choriogonadotropin beta, combined ovarian stimulation, long GnRH agonist protocol and recombinant hCG.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin) in 620 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Human reproduction (Oxford, England)), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.